Update in the pharmacotherapy for neuropathic pain treatment

Abstract

Abstract: Neuropathic pain is a form of chronic pain caused by nervous lesions and significantly reduces patients' quality of life. Nowadays pharmacotherapy is still the main therapeutic paradigm. The article summarizes the underlying molecular pharmacologic mechanisms of the drugs used in the pharmacotherapy as well as their application characteristics in the clinical practice, and points out the perspective of the development of targeted drugs on the basis of elucidating the mechanisms of neuropathic pain.

Key words: Neuropathic Pain, Pharmacotherapy, Analgesic, Review

CLC Number:

R741.02

LI Zhao-sheng, LIN Hong, SHA Mo, DING Zhen-qi. Update in the pharmacotherapy for neuropathic pain treatment[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(9): 1076-1080.

References

[1] Bouhassira D, Lanteri-Minet M, Attal N, et al. Prevalence of chronic pain with neuropathic characteristics in the general population[J]. Pain, 2008,136(3):380-387.
[2] Simpson DM, Schifitto G, Clifford DB, et al. Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial[J]. Neurology, 2010,74(5):413-420.
[3] Fink K, Meder W, Dooley DJ, et al. Inhibition of neuronal Ca(2+) influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices[J].Br J Pharmacol, 2000,130(4):900-906
[4] Jensen MP, Chiang YK, Wu J. Assessment of pain quality in a clinical trial of gabapentin extended release for postherpetic neuralgia[J]. Clin J Pain, 2009,25(4):286-292.
[5] Backonja MM, Canafax DM, Cundy KC. Efficacy of gabapentin enacarbil vs placebo in patients with postherpetic neuralgia and a pharmacokinetic comparison with oral gabapentin[J]. Pain Med, 2011,12(7):1098-1108.
[6] Berger A, Dukes E, Mercadante S, et al. Use of antiepileptics and tricyclic antidepressants in cancer patients with neuropathic pain[J]. Eur J Cancer Care (Engl), 2006,15(2):138-145.
[7] Kopsky DJ, Hesselink JM. High doses of topical amitriptyline in neuropathic pain: two cases and literature review[J]. Pain Pract, 2012,12(2):148-153.
[8] Rowbotham MC, Reisner LA, Davies PS, et al. Treatment response in antidepressant-naive postherpetic neuralgia patients: double-blind, randomized trial[J]. J Pain, 2005,6(11):741-746.
[9] Attal N, Cruccu G, Haanpaa M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain[J]. Eur J Neurol, 2006,13(11):1153-1169.
[10] Tanenberg RJ, Irving GA, Risser RC, et al. Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison[J]. Mayo Clin Proc, 2011,86(7):615-626.
[11] Skljarevski V, Desaiah D, Zhang Q, et al. Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain[J]. Diabetes Metab Res Rev, 2009,25(7):623-631.
[12] Enomoto T, Yamashita A, Torigoe K, et al. Effects of mirtazapine on sleep disturbance under neuropathic pain-like state[J]. Synapse, 2012,66(6):483-488.
[13] Kanai A, Kumaki C, Niki Y, et al. Efficacy of a metered-dose 8% lidocaine pump spray for patients with post-herpetic neuralgia[J]. Pain Med, 2009,10(5):902-909.
[14] Kern KU, Kohl M, Kiefer RT. [Lidocaine patch for therapy of neuropathic and non-neuropathic pain. A clinical case series of 87 patients] [J]. Nervenarzt, 2010,81(12):1490-1497.
[15] Rehm S, Binder A, Baron R. Post-herpetic neuralgia: 5% lidocaine medicated plaster, pregabalin, or a combination of both? A randomized, open, clinical effectiveness study[J]. Curr Med Res Opin, 2010,26(7):1607-1619.
[16] Hermanns K, Junker U, Nolte T. Prolonged-release oxycodone/naloxone in the treatment of neuropathic pain - results from a large observational study[J]. Expert Opin Pharmacother, 2012,13(3):299-311.
[17] Altier N, Dion D, Boulanger A, et al. Management of chronic neuropathic pain with methadone: a review of 13 cases[J]. Clin J Pain, 2005,21(4):364-369.
[18] Ranoux D, Attal N, Morain F, et al. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain[J]. Ann Neurol, 2008,64(3):274-283.
[19] 范荣兰,刘双玉,李亚玲,等.A型肉毒毒素治疗带状疱疹后顽固性神经痛20例[J].医药导报,2010,29(11):1452-1453.DOI:10.3870/yydb.2010.11.019.
[20] Backonja MM, Malan TP, Vanhove GF, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension[J]. Pain Med, 2010,11(4):600-608.
[21] Chen JY, Chang CY, Feng PH, et al. Plasma vitamin C is lower in postherpetic neuralgia patients and administration of vitamin C reduces spontaneous pain but not brush-evoked pain[J]. Clin J Pain, 2009,25(7):562-569.
[22] Gilron I, Bailey J M, Tu D, et al. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial[J]. Lancet, 2009,374(9697):1252-1261.
[23] Patarica-Huber E, Boskov N, Pjevic M. Multimodal approach to therapy-related neuropathic pain in breast cancer[J]. J BUON, 2011,16(1):40-45.
[24] Mankovsky T, Lynch M, Clark A, et al. Pain catastrophizing predicts poor response to topical analgesics in patients with neuropathic pain[J]. Pain Res Manag, 2012,17(1):10-14.